Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A.

Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.

PMID:
29808007
2.

Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene.

Casucci M, Falcone L, Camisa B, Norelli M, Porcellini S, Stornaiuolo A, Ciceri F, Traversari C, Bordignon C, Bonini C, Bondanza A.

Front Immunol. 2018 Mar 21;9:507. doi: 10.3389/fimmu.2018.00507. eCollection 2018.

3.

Detection and Characterization of CD8+ Autoreactive Memory Stem T Cells in Patients With Type 1 Diabetes.

Vignali D, Cantarelli E, Bordignon C, Canu A, Citro A, Annoni A, Piemonti L, Monti P.

Diabetes. 2018 May;67(5):936-945. doi: 10.2337/db17-1390. Epub 2018 Mar 5.

4.

Integrating T cell metabolism in cancer immunotherapy.

Dugnani E, Pasquale V, Bordignon C, Canu A, Piemonti L, Monti P.

Cancer Lett. 2017 Dec 28;411:12-18. doi: 10.1016/j.canlet.2017.09.039. Epub 2017 Sep 30. Review.

PMID:
28974448
5.

Twenty-five years of gene therapy for genetic diseases and leukemia: The road to marketing authorization of the first ex vivo gene therapies.

Bordignon C.

J Autoimmun. 2017 Dec;85:98-102. doi: 10.1016/j.jaut.2017.07.005. Epub 2017 Jul 16. Review. No abstract available.

PMID:
28724503
6.

Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes.

Piovan C, Marin V, Scavullo C, Corna S, Giuliani E, Bossi S, Galy A, Fenard D, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2017 Mar 8;5:22-30. doi: 10.1016/j.omtm.2017.02.003. eCollection 2017 Jun 16.

7.

Ultrasmall polymeric nanocarriers for drug delivery to podocytes in kidney glomerulus.

Bruni R, Possenti P, Bordignon C, Li M, Ordanini S, Messa P, Rastaldi MP, Cellesi F.

J Control Release. 2017 Jun 10;255:94-107. doi: 10.1016/j.jconrel.2017.04.005. Epub 2017 Apr 7.

PMID:
28395969
8.

Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.

Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17.

9.

T-cell Metabolism as a Target to Control Autoreactive T Cells in β-Cell Autoimmunity.

Bordignon C, Canu A, Dyczko A, Leone S, Monti P.

Curr Diab Rep. 2017 May;17(5):24. doi: 10.1007/s11892-017-0848-5. Review.

10.

The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice.

Lanterna C, Musumeci A, Raccosta L, Corna G, Moresco M, Maggioni D, Fontana R, Doglioni C, Bordignon C, Traversari C, Russo V.

Cancer Immunol Immunother. 2016 Nov;65(11):1303-1315. Epub 2016 Aug 12.

PMID:
27520505
11.

24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development.

Soncini M, Corna G, Moresco M, Coltella N, Restuccia U, Maggioni D, Raccosta L, Lin CY, Invernizzi F, Crocchiolo R, Doglioni C, Traversari C, Bachi A, Bernardi R, Bordignon C, Gustafsson JÅ, Russo V.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6219-E6227. Epub 2016 Sep 26.

12.

RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

Marin V, Stornaiuolo A, Piovan C, Corna S, Bossi S, Pema M, Giuliani E, Scavullo C, Zucchelli E, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2016 May 11;3:16033. doi: 10.1038/mtm.2016.33. eCollection 2016.

13.

Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory.

Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D'Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, Peccatori J, Aiuti A, Ambrosi A, Biasco L, Bondanza A, Lambiase A, Traversari C, Vago L, von Kalle C, Schmidt M, Bordignon C, Ciceri F, Bonini C.

Sci Transl Med. 2015 Dec 9;7(317):317ra198. doi: 10.1126/scitranslmed.aac8265. Erratum in: Sci Transl Med. 2015 Dec 23;7(319):319er9. D'Agostino, Mattio [corrected to D'Agostino, Mattia].

PMID:
26659572
14.

The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.

Porcellini S, Asperti C, Valentinis B, Tiziano E, Mangia P, Bordignon C, Rizzardi GP, Traversari C.

Oncoimmunology. 2015 Jul 1;4(10):e1041700. eCollection 2015 Oct.

15.

Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.

Di Lullo G, Marcatti M, Heltai S, Brunetto E, Tresoldi C, Bondanza A, Bonini C, Ponzoni M, Tonon G, Ciceri F, Bordignon C, Protti MP.

Oncoimmunology. 2015 Feb 3;4(5):e1005460. eCollection 2015 May.

16.

Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall.

Noviello M, Forcina A, Veronica V, Crocchiolo R, Stanghellini MT, Carrabba M, Greco R, Vago L, Giglio F, Assanelli A, Carbone MR, Magnani Z, Crippa F, Corti C, Bernardi M, Peccatori J, Bordignon C, Ciceri F, Bonini C, Bondanza A.

Bone Marrow Transplant. 2015 Sep;50(9):1262-4. doi: 10.1038/bmt.2015.132. Epub 2015 Jun 15. No abstract available.

PMID:
26076126
17.

Haploidentical HSCT: a 15-year experience at San Raffaele.

Bonini C, Peccatori J, Stanghellini MT, Vago L, Bondanza A, Cieri N, Greco R, Bernardi M, Corti C, Oliveira G, Zappone E, Traversari C, Bordignon C, Ciceri F.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S67-71. doi: 10.1038/bmt.2015.99.

PMID:
26039212
18.

Improving the safety of cell therapy with the TK-suicide gene.

Greco R, Oliveira G, Stanghellini MT, Vago L, Bondanza A, Peccatori J, Cieri N, Marktel S, Mastaglio S, Bordignon C, Bonini C, Ciceri F.

Front Pharmacol. 2015 May 5;6:95. doi: 10.3389/fphar.2015.00095. eCollection 2015. Review.

19.

Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation.

Cieri N, Oliveira G, Greco R, Forcato M, Taccioli C, Cianciotti B, Valtolina V, Noviello M, Vago L, Bondanza A, Lunghi F, Marktel S, Bellio L, Bordignon C, Bicciato S, Peccatori J, Ciceri F, Bonini C.

Blood. 2015 Apr 30;125(18):2865-74. doi: 10.1182/blood-2014-11-608539. Epub 2015 Mar 3.

20.

In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells.

Biasco L, Scala S, Basso Ricci L, Dionisio F, Baricordi C, Calabria A, Giannelli S, Cieri N, Barzaghi F, Pajno R, Al-Mousa H, Scarselli A, Cancrini C, Bordignon C, Roncarolo MG, Montini E, Bonini C, Aiuti A.

Sci Transl Med. 2015 Feb 4;7(273):273ra13. doi: 10.1126/scitranslmed.3010314.

PMID:
25653219
21.

Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF.

Di Matteo P, Mangia P, Tiziano E, Valentinis B, Porcellini S, Doglioni C, Sanvito F, Bordignon C, Rizzardi GP, Traversari C.

Clin Exp Metastasis. 2015 Mar;32(3):289-300. doi: 10.1007/s10585-015-9704-7. Epub 2015 Feb 4.

PMID:
25648442
22.

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation.

Crucitti L, Crocchiolo R, Toffalori C, Mazzi B, Greco R, Signori A, Sizzano F, Chiesa L, Zino E, Lupo Stanghellini MT, Assanelli A, Carrabba MG, Marktel S, Marcatti M, Bordignon C, Corti C, Bernardi M, Peccatori J, Bonini C, Fleischhauer K, Ciceri F, Vago L.

Leukemia. 2015 May;29(5):1143-52. doi: 10.1038/leu.2014.314. Epub 2014 Nov 5.

PMID:
25371177
23.

Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.

Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, Noviello M, Messina C, Crotta A, Assanelli A, Marktel S, Olek S, Mastaglio S, Giglio F, Crucitti L, Lorusso A, Guggiari E, Lunghi F, Carrabba M, Tassara M, Battaglia M, Ferraro A, Carbone MR, Oliveira G, Roncarolo MG, Rossini S, Bernardi M, Corti C, Marcatti M, Patriarca F, Zecca M, Locatelli F, Bordignon C, Fleischhauer K, Bondanza A, Bonini C, Ciceri F.

Leukemia. 2015 Feb;29(2):396-405. doi: 10.1038/leu.2014.180. Epub 2014 Jun 4.

PMID:
24897508
24.

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma.

Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, Gentner B, Gullotta F, Ponzoni M, Bernardi M, Marcatti M, Saudemont A, Bordignon C, Savoldo B, Ciceri F, Naldini L, Dotti G, Bonini C, Bondanza A.

Blood. 2013 Nov 14;122(20):3461-72. doi: 10.1182/blood-2013-04-493361. Epub 2013 Sep 9.

25.

The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils.

Raccosta L, Fontana R, Maggioni D, Lanterna C, Villablanca EJ, Paniccia A, Musumeci A, Chiricozzi E, Trincavelli ML, Daniele S, Martini C, Gustafsson JA, Doglioni C, Feo SG, Leiva A, Ciampa MG, Mauri L, Sensi C, Prinetti A, Eberini I, Mora JR, Bordignon C, Steffensen KR, Sonnino S, Sozzani S, Traversari C, Russo V.

J Exp Med. 2013 Aug 26;210(9):1711-28. doi: 10.1084/jem.20130440. Epub 2013 Jul 29.

26.

Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.

Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L.

Science. 2013 Aug 23;341(6148):1233158. doi: 10.1126/science.1233158. Epub 2013 Jul 11.

27.

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.

Di Matteo P, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi GP.

Br J Cancer. 2013 Jul 23;109(2):360-9. doi: 10.1038/bjc.2013.347. Epub 2013 Jul 4.

28.

RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S, Salvatori F, Mavilio F, Bordignon C, Rizzardi GP, Bovolenta C.

Hum Gene Ther Methods. 2013 Aug;24(4):228-40. doi: 10.1089/hgtb.2012.190. Epub 2013 Aug 3.

29.

Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs.

Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, Mognol P, Thibaud JL, Galvez BG, Barthélémy I, Perani L, Mantero S, Guttinger M, Pansarasa O, Rinaldi C, De Angelis MG, Torrente Y, Bordignon C, Bottinelli R, Cossu G.

Nature. 2013 Feb 20;494(7438):506. doi: 10.1038/nature11976. Epub 2013 Feb 20. No abstract available.

PMID:
23426261
30.

Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene.

Casucci M, Perna SK, Falcone L, Camisa B, Magnani Z, Bernardi M, Crotta A, Tresoldi C, Fleischhauer K, Ponzoni M, Gregori S, Caligaris Cappio F, Ciceri F, Bordignon C, Cignetti A, Bondanza A, Bonini C.

Mol Ther. 2013 Feb;21(2):466-75. doi: 10.1038/mt.2012.227. Epub 2012 Nov 13.

31.

Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours.

Zucali PA, Simonelli M, De Vincenzo F, Lorenzi E, Perrino M, Bertossi M, Finotto R, Naimo S, Balzarini L, Bonifacio C, Timofeeva I, Rossoni G, Mazzola G, Lambiase A, Bordignon C, Santoro A.

Br J Cancer. 2013 Jan 15;108(1):58-63. doi: 10.1038/bjc.2012.506. Epub 2012 Nov 20.

32.

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors.

Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, Lupo-Stanghellini MT, Mavilio F, Mondino A, Bicciato S, Recchia A, Bonini C.

Blood. 2013 Jan 24;121(4):573-84. doi: 10.1182/blood-2012-05-431718. Epub 2012 Nov 15.

33.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.

Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M.

Int J Cancer. 2013 Jun 1;132(11):2557-66. doi: 10.1002/ijc.27939. Epub 2012 Dec 13.

34.

De novo design of a tumor-penetrating peptide.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E.

Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14.

35.

Comparing the responsiveness of the assessment of motor and process skills and the functional independence measure.

Fioravanti AM, Bordignon CM, Pettit SM, Woodhouse LJ, Ansley BJ.

Can J Occup Ther. 2012 Jun;79(3):167-74.

PMID:
22822694
36.

T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.

Vago L, Oliveira G, Bondanza A, Noviello M, Soldati C, Ghio D, Brigida I, Greco R, Lupo Stanghellini MT, Peccatori J, Fracchia S, Del Fiacco M, Traversari C, Aiuti A, Del Maschio A, Bordignon C, Ciceri F, Bonini C.

Blood. 2012 Aug 30;120(9):1820-30. doi: 10.1182/blood-2012-01-405670. Epub 2012 Jun 18.

37.

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.

Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C.

Br J Cancer. 2012 Jun 26;107(1):37-42. doi: 10.1038/bjc.2012.233. Epub 2012 May 29.

38.

Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT.

Toffalori C, Cavattoni I, Deola S, Mastaglio S, Giglio F, Mazzi B, Assanelli A, Peccatori J, Bordignon C, Bonini C, Cortelazzo S, Ciceri F, Fleischhauer K, Vago L.

Blood. 2012 May 17;119(20):4813-5. doi: 10.1182/blood-2012-02-411686. No abstract available.

39.

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer.

Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C.

Nat Med. 2012 May;18(5):807-815. doi: 10.1038/nm.2700.

40.

A dual role for genetically modified lymphocytes in cancer immunotherapy.

Russo V, Bondanza A, Ciceri F, Bregni M, Bordignon C, Traversari C, Bonini C.

Trends Mol Med. 2012 Apr;18(4):193-200. doi: 10.1016/j.molmed.2011.12.003. Epub 2012 Jan 7. Review.

PMID:
22230382
41.

Extracorporeal membrane oxygenation: a new way to study toxic drugs in chronic diseases.

Landoni G, Greco M, Ruggeri L, Zangrillo A, Bordignon C.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):e54-5. doi: 10.1053/j.jvca.2011.06.014. Epub 2011 Aug 20. No abstract available.

PMID:
21862349
42.

IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors.

Bondanza A, Hambach L, Aghai Z, Nijmeijer B, Kaneko S, Mastaglio S, Radrizzani M, Fleischhauer K, Ciceri F, Bordignon C, Bonini C, Goulmy E.

Blood. 2011 Jun 16;117(24):6469-78. doi: 10.1182/blood-2010-11-320366. Epub 2011 Apr 29.

43.

Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.

Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C.

Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9.

44.

Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.

Desar IM, van Herpen CM, van Asten JJ, Fiedler W, Marreaud S, Timmer-Bonte JN, ter Voert EG, Lambiase A, Bordignon C, Heerschap A, van Laarhoven HW.

Eur J Radiol. 2011 Dec;80(3):655-61. doi: 10.1016/j.ejrad.2010.08.045. Epub 2010 Sep 21.

PMID:
20863638
45.

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.

Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C.

Ann Oncol. 2011 Apr;22(4):973-8. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20.

46.

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C.

Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17.

47.

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.

Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C.

Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12.

PMID:
20708923
48.

Progress and prospects: graft-versus-host disease.

Mastaglio S, Stanghellini MT, Bordignon C, Bondanza A, Ciceri F, Bonini C.

Gene Ther. 2010 Nov;17(11):1309-17. doi: 10.1038/gt.2010.83. Epub 2010 May 27. Review.

PMID:
20508597
49.

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.

Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C.

J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649. Epub 2010 Apr 20.

PMID:
20406925
50.

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM.

Clin Cancer Res. 2010 Feb 15;16(4):1315-23. doi: 10.1158/1078-0432.CCR-09-1621. Epub 2010 Feb 9.

Supplemental Content

Loading ...
Support Center